Skip to main content
Erschienen in: Digestive Diseases and Sciences 3/2012

01.03.2012 | Original Article

Endoscopic Management of Duodenal Adenomas in Familial Adenomatous Polyposis—A Single-Center Experience

verfasst von: Sathya Jaganmohan, Patrick M. Lynch, Ramu P. Raju, William A. Ross, Jeffrey E. Lee, Gottumukkala S. Raju, Manoop S. Bhutani, Jason B. Fleming, Jeffrey H. Lee

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Duodenal lesions (DLS) are common in patients with familial adenomatosis polyposis (FAP), and screening for duodenal adenocarcinoma (DA) is currently recommended. Endoscopic treatment of DLS is controversial.

Aim

To report management and outcomes of endoscopic therapy for DLS in patients with FAP.

Methods

The records of patients with FAP who underwent endoscopic surveillance or therapy for DLS over a 15-year period were reviewed. Endoscopic intervention included endoscopic surveillance with biopsies, argon plasma coagulation (APC), endoscopic mucosal resection (EMR), EMR with APC, and ampullectomy. Main outcome measurements were recurrence and histology of DLS after endoscopic therapy, complications of endoscopic therapy, and need for duodenectomy.

Results

Seventy-one patients with FAP and DLS were identified from our endoscopy database as undergoing upper endoscopy for screening and/or surveillance (1995–2009). Mean follow up was 4.5 years (1–15 years). Seventy of the seventy-one (98.5%) patients had multiple flat DLS. Most of the patients were followed with yearly biopsies. APC was performed in 17 patients and EMR was performed in eight patients; in five of the eight EMR patients, APC was also performed to treat the edges of EMR site. During the follow up, 17/55 (31%) patients had histological progression (HP). HP was seen in 5/16 (31%) patients who underwent APC (one was lost to follow-up) and 12/40 (30%) patients followed with biopsies alone. Recurrence of lesions was noted in all patients. Two patients underwent duodenectomy. None of the patients developed DA during follow up.

Conclusions

Endoscopic surveillance with directed endotherapy for DLS in FAP is feasible and safe when diligently performed.
Literatur
1.
Zurück zum Zitat Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet. 1988;1:1149–1151.PubMedCrossRef Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet. 1988;1:1149–1151.PubMedCrossRef
2.
Zurück zum Zitat Heiskanen I, Kellokumpu I, Jarvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy. 1999;31:412–416.PubMedCrossRef Heiskanen I, Kellokumpu I, Jarvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy. 1999;31:412–416.PubMedCrossRef
3.
Zurück zum Zitat Bulow S, Bjork J, Christensen IJ, et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut. 2004;53:381–386.PubMedCrossRef Bulow S, Bjork J, Christensen IJ, et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut. 2004;53:381–386.PubMedCrossRef
4.
Zurück zum Zitat Adler DG, Qureshi W, Davila R, et al. The role of endoscopy in ampullary and duodenal adenomas. Gastrointest Endosc. 2006;64:849–854.PubMedCrossRef Adler DG, Qureshi W, Davila R, et al. The role of endoscopy in ampullary and duodenal adenomas. Gastrointest Endosc. 2006;64:849–854.PubMedCrossRef
5.
Zurück zum Zitat Burke CA, Beck GJ, Church JM, van Stolk RU. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. Gastrointest Endosc. 1999;49:358–364.PubMedCrossRef Burke CA, Beck GJ, Church JM, van Stolk RU. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. Gastrointest Endosc. 1999;49:358–364.PubMedCrossRef
6.
Zurück zum Zitat Vasen HF, Bulow S, Myrhoj T, et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut. 1997;40:716–719.PubMedCrossRef Vasen HF, Bulow S, Myrhoj T, et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut. 1997;40:716–719.PubMedCrossRef
7.
Zurück zum Zitat Morpurgo E, Vitale GC, Galandiuk S, Kimberling J, Ziegler C, Polk HC Jr. Clinical characteristics of familial adenomatous polyposis and management of duodenal adenomas. J Gastrointest Surg. 2004;8:559–564.PubMedCrossRef Morpurgo E, Vitale GC, Galandiuk S, Kimberling J, Ziegler C, Polk HC Jr. Clinical characteristics of familial adenomatous polyposis and management of duodenal adenomas. J Gastrointest Surg. 2004;8:559–564.PubMedCrossRef
8.
Zurück zum Zitat Regula J, MacRobert AJ, Gorchein A, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX–a pilot study. Gut. 1995;36:67–75.PubMedCrossRef Regula J, MacRobert AJ, Gorchein A, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX–a pilot study. Gut. 1995;36:67–75.PubMedCrossRef
9.
Zurück zum Zitat Mlkvy P, Messmann H, Debinski H, et al. Photodynamic therapy for polyps in familial adenomatous polyposis—a pilot study. Eur J Cancer. 1995;31A:1160–1165.PubMed Mlkvy P, Messmann H, Debinski H, et al. Photodynamic therapy for polyps in familial adenomatous polyposis—a pilot study. Eur J Cancer. 1995;31A:1160–1165.PubMed
10.
Zurück zum Zitat Abulafi AM, Allardice JT, Williams NS, van Someren N, Swain CP, Ainley C. Photodynamic therapy for malignant tumours of the ampulla of Vater. Gut. 1995;36:853–856.PubMedCrossRef Abulafi AM, Allardice JT, Williams NS, van Someren N, Swain CP, Ainley C. Photodynamic therapy for malignant tumours of the ampulla of Vater. Gut. 1995;36:853–856.PubMedCrossRef
11.
Zurück zum Zitat Soravia C, Berk T, Haber G, Cohen Z, Gallinger S. Management of advanced duodenal polyposis in familial adenomatous polyposis. J Gastrointest Surg. 1997;1:474–478.PubMedCrossRef Soravia C, Berk T, Haber G, Cohen Z, Gallinger S. Management of advanced duodenal polyposis in familial adenomatous polyposis. J Gastrointest Surg. 1997;1:474–478.PubMedCrossRef
12.
Zurück zum Zitat Norton ID, Gostout CJ, Baron TH, Geller A, Petersen BT, Wiersema MJ. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc. 2002;56:239–243.PubMedCrossRef Norton ID, Gostout CJ, Baron TH, Geller A, Petersen BT, Wiersema MJ. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc. 2002;56:239–243.PubMedCrossRef
13.
Zurück zum Zitat Spigelman AD, Crofton-Sleigh C, Venitt S, Phillips RK. Mutagenicity of bile and duodenal adenomas in familial adenomatous polyposis. Br J Surg. 1990;77:878–881.PubMedCrossRef Spigelman AD, Crofton-Sleigh C, Venitt S, Phillips RK. Mutagenicity of bile and duodenal adenomas in familial adenomatous polyposis. Br J Surg. 1990;77:878–881.PubMedCrossRef
14.
Zurück zum Zitat Esaki M, Matsumoto T, Yao S, et al. Immunohistochemical characteristics of duodenal adenomas in familial adenomatous polyposis with special reference to cell kinetics. Hum Pathol. 2005;36:66–73.PubMedCrossRef Esaki M, Matsumoto T, Yao S, et al. Immunohistochemical characteristics of duodenal adenomas in familial adenomatous polyposis with special reference to cell kinetics. Hum Pathol. 2005;36:66–73.PubMedCrossRef
15.
Zurück zum Zitat Bjork J, Akerbrant H, Iselius L, et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology. 2001;121:1127–1135.PubMedCrossRef Bjork J, Akerbrant H, Iselius L, et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology. 2001;121:1127–1135.PubMedCrossRef
16.
Zurück zum Zitat Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993;80:1618–1619.PubMedCrossRef Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993;80:1618–1619.PubMedCrossRef
17.
Zurück zum Zitat Wallace MH, Forbes A, Beveridge IG, et al. Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis. Dis Colon Rectum. 2001;44:1585–1589.PubMedCrossRef Wallace MH, Forbes A, Beveridge IG, et al. Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis. Dis Colon Rectum. 2001;44:1585–1589.PubMedCrossRef
18.
Zurück zum Zitat Johnson MD, Mackey R, Brown N, Church J, Burke C, Walsh RM. Outcome based on management for duodenal adenomas: sporadic versus familial disease. J Gastrointest Surg. 2010;14:229–235.PubMedCrossRef Johnson MD, Mackey R, Brown N, Church J, Burke C, Walsh RM. Outcome based on management for duodenal adenomas: sporadic versus familial disease. J Gastrointest Surg. 2010;14:229–235.PubMedCrossRef
19.
Zurück zum Zitat Nugent KP, Spigelman AD, Williams CB, Talbot IC, Phillips RK. Surveillance of duodenal polyps in familial adenomatous polyposis: progress report. J R Soc Med. 1994;87:704–706.PubMed Nugent KP, Spigelman AD, Williams CB, Talbot IC, Phillips RK. Surveillance of duodenal polyps in familial adenomatous polyposis: progress report. J R Soc Med. 1994;87:704–706.PubMed
20.
Zurück zum Zitat Saurin JC, Gutknecht C, Napoleon B, et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol. 2004;22:493–498.PubMedCrossRef Saurin JC, Gutknecht C, Napoleon B, et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol. 2004;22:493–498.PubMedCrossRef
21.
Zurück zum Zitat Matsumoto T, Iida M, Nakamura S, et al. Natural history of ampullary adenoma in familial adenomatous polyposis: reconfirmation of benign nature during extended surveillance. Am J Gastroenterol. 2000;95:1557–1562.PubMedCrossRef Matsumoto T, Iida M, Nakamura S, et al. Natural history of ampullary adenoma in familial adenomatous polyposis: reconfirmation of benign nature during extended surveillance. Am J Gastroenterol. 2000;95:1557–1562.PubMedCrossRef
22.
Zurück zum Zitat Bertoni G, Sassatelli R, Nigrisoli E, et al. Dysplastic changes in gastric fundic gland polyps of patients with familial adenomatous polyposis. Ital J Gastroenterol Hepatol. 1999;31:192–197.PubMed Bertoni G, Sassatelli R, Nigrisoli E, et al. Dysplastic changes in gastric fundic gland polyps of patients with familial adenomatous polyposis. Ital J Gastroenterol Hepatol. 1999;31:192–197.PubMed
Metadaten
Titel
Endoscopic Management of Duodenal Adenomas in Familial Adenomatous Polyposis—A Single-Center Experience
verfasst von
Sathya Jaganmohan
Patrick M. Lynch
Ramu P. Raju
William A. Ross
Jeffrey E. Lee
Gottumukkala S. Raju
Manoop S. Bhutani
Jason B. Fleming
Jeffrey H. Lee
Publikationsdatum
01.03.2012
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 3/2012
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1917-2

Weitere Artikel der Ausgabe 3/2012

Digestive Diseases and Sciences 3/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.